ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Outcomes with the MitraClip® device in the ACCESS-EUrope Phase I trial

Sunday, October 6, 2013

Submitted by

Source

Source Name: European Journal of Cardio-Thoracic Surgery

Source URL: http://ejcts.oxfordjournals.org/content/44/4/e280.abstract

Author(s)

Hermann Reichenspurner, Wolfgang Schillinger, Stephan Baldus, Jörg Hausleiter, Christian Butter, Ulrich Schäefer, Giovanni Pedrazzini, and Francesco Maisano

The MitraClip Therapy Economic and Clinical Outcomes Study Europe (ACCESS-EU) enroled 117 patients with degenerative mitral regurgitation (MR) considered ineligible for surgery. Mortalities at 30 days and 12 months were 6.0 and 17.1%, respectively. At 12 months, 74.6% (53 of 71) of patients in follow-up achieved significant reductions in MR and improved clinical outcomes. This complementary non-surgical intervention should be indicated by an inter-disciplinary team of cardiologists and cardiac surgeons.